Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
|Articles|March 5, 2013
John Glaser, PhD, Discusses Healthcare Delivery Systems
John Glaser, PhD, chief executive officer, Health Services, Siemens Healthcare, says that healthcare is going through a transformation based on payment reform changes.
Advertisement
John Glaser, PhD, chief executive officer, Health Services, Siemens Healthcare, says that healthcare is going through a transformation based on payment reform changes. Without sophisticated analytics, providers would not be able to understand whether the care they deliver is safe or efficient.
"One needs analytics to managed those processes of care which, at the end of the day, form the lifeblood of the provider organization," said Dr Glaser.
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5